Logo image of JBIO

JADE BIOSCIENCES INC (JBIO) Stock Fundamental Analysis

NASDAQ:JBIO - US0080642061 - Common Stock

7.77 USD
-0.01 (-0.13%)
Last: 9/5/2025, 8:23:40 PM
7.77 USD
0 (0%)
After Hours: 9/5/2025, 8:23:40 PM
Fundamental Rating

3

Taking everything into account, JBIO scores 3 out of 10 in our fundamental rating. JBIO was compared to 542 industry peers in the Biotechnology industry. While JBIO has a great health rating, there are worries on its profitability. JBIO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

JBIO had negative earnings in the past year.
In the past year JBIO has reported a negative cash flow from operations.
JBIO had negative earnings in each of the past 5 years.
In the past 5 years JBIO always reported negative operating cash flow.
JBIO Yearly Net Income VS EBIT VS OCF VS FCFJBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of JBIO (-25.15%) is better than 72.51% of its industry peers.
The Return On Equity of JBIO (-27.94%) is better than 78.78% of its industry peers.
Industry RankSector Rank
ROA -25.15%
ROE -27.94%
ROIC N/A
ROA(3y)-61.34%
ROA(5y)-80.96%
ROE(3y)-66.92%
ROE(5y)-110.13%
ROIC(3y)N/A
ROIC(5y)N/A
JBIO Yearly ROA, ROE, ROICJBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for JBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JBIO Yearly Profit, Operating, Gross MarginsJBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

JBIO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, JBIO has more shares outstanding
JBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
JBIO Yearly Shares OutstandingJBIO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K
JBIO Yearly Total Debt VS Total AssetsJBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

JBIO has an Altman-Z score of 6.33. This indicates that JBIO is financially healthy and has little risk of bankruptcy at the moment.
JBIO's Altman-Z score of 6.33 is fine compared to the rest of the industry. JBIO outperforms 78.60% of its industry peers.
There is no outstanding debt for JBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.33
ROIC/WACCN/A
WACCN/A
JBIO Yearly LT Debt VS Equity VS FCFJBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

JBIO has a Current Ratio of 10.31. This indicates that JBIO is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 10.31, JBIO belongs to the best of the industry, outperforming 82.29% of the companies in the same industry.
JBIO has a Quick Ratio of 10.31. This indicates that JBIO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 10.31, JBIO belongs to the top of the industry, outperforming 82.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.31
Quick Ratio 10.31
JBIO Yearly Current Assets VS Current LiabilitesJBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

JBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.47%, which is quite impressive.
EPS 1Y (TTM)72.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.45% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y95.8%
EPS Next 2Y40.49%
EPS Next 3Y25.35%
EPS Next 5Y14.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JBIO Yearly EPS VS EstimatesJBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 -20 -40 -60 -80 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

JBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year JBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JBIO Price Earnings VS Forward Price EarningsJBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JBIO Per share dataJBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as JBIO's earnings are expected to grow with 25.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.49%
EPS Next 3Y25.35%

More info and screens

4

5. Dividend

5.1 Amount

JBIO has a Yearly Dividend Yield of 1081.08%, which is a nice return.
JBIO's Dividend Yield is rather good when compared to the industry average which is at 166.20. JBIO pays more dividend than 100.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.41, JBIO pays a better dividend.
Industry RankSector Rank
Dividend Yield 1081.08%

5.2 History

JBIO is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
JBIO Yearly Dividends per shareJBIO Yearly Dividends per shareYearly Dividends per share 2025 20 40 60 80

5.3 Sustainability

DPN/A
EPS Next 2Y40.49%
EPS Next 3Y25.35%
JBIO Yearly Income VS Free CF VS DividendJBIO Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2019 2020 2021 2022 2023 2024 -20M -40M -60M

More info and screens

JADE BIOSCIENCES INC

NASDAQ:JBIO (9/5/2025, 8:23:40 PM)

After market: 7.77 0 (0%)

7.77

-0.01 (-0.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners38.88%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner Change1.37%
Market Cap253.54M
Analysts85.45
Price Target17.09 (119.95%)
Short Float %6.27%
Short Ratio6.52
Dividend
Industry RankSector Rank
Dividend Yield 1081.08%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date04-29 2025-04-29 (84)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.8%
Min EPS beat(2)-94.83%
Max EPS beat(2)63.24%
EPS beat(4)3
Avg EPS beat(4)-0.09%
Min EPS beat(4)-94.83%
Max EPS beat(4)63.24%
EPS beat(8)3
Avg EPS beat(8)-1.56%
EPS beat(12)4
Avg EPS beat(12)-3%
EPS beat(16)5
Avg EPS beat(16)-6.89%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.52%
PT rev (3m)-79.49%
EPS NQ rev (1m)-18.04%
EPS NQ rev (3m)-154.44%
EPS NY rev (1m)39.22%
EPS NY rev (3m)39.81%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.26
EV/EBITDA N/A
EPS(TTM)-30.26
EYN/A
EPS(NY)-2.25
Fwd EYN/A
FCF(TTM)-2.03
FCFYN/A
OCF(TTM)-2.02
OCFYN/A
SpS0
BVpS6.18
TBVpS6.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.15%
ROE -27.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.34%
ROA(5y)-80.96%
ROE(3y)-66.92%
ROE(5y)-110.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.31
Quick Ratio 10.31
Altman-Z 6.33
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.14%
EPS Next Y95.8%
EPS Next 2Y40.49%
EPS Next 3Y25.35%
EPS Next 5Y14.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y41.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-29.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.55%
OCF growth 3YN/A
OCF growth 5YN/A